BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia.
Lucas
Claire M
CM
Harris
Robert J
RJ
Giannoudis
Athina
A
Knight
Katy
K
Watmough
Sarah J
SJ
Clark
Richard E
RE
D048868:Adaptor Proteins, Signal Transducing / Q000097:blood*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood; D009687:Nuclear Proteins / Q000097:blood*; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
D048868:Adaptor Proteins, Signal Transducing; D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; C082869:CRKL protein; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate